IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.

Cohort studyFrontiers in immunology· 2026

IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.

Raquel Diaz-Simon, Antonio Lalueza, Manuel Serrano … Antonio Serrano

Read paper

HematologyCohort studyPrognosisQ1IF 6.4

IgA anti-β2-glycoprotein I antibodies independently associated with venous thromboembolism.

IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.

Raquel Diaz-Simon … Antonio Serrano

Frontiers in immunology · 2026

Background

Venous thromboembolism (venous thromboembolism) is the third most common cause of cardiovascular death.

Purpose

To assess the role of criteria and non-criteria antiphospholipid antibodies in patients with acute venous thromboembolism.

Methods

A cohort of 181 patients with venous thromboembolism was followed for 2 years.

n = 181 patients

Results

OR 4.31

IgA antibody carriers had over four times higher odds of venous thromboembolism

n = 181 patients

More results

Criteria aPL were detected in 8.8% of patients, whereas non-criteria aPL were present in 23.8%.

Criteria aPL were independently associated with overall venous thromboembolism (OR 7.09, p=0.021) and unprovoked venous thromboembolism (OR 4.61, p=0.021).

“

Conclusion

IgA aB2GP1 antibodies are independently associated with venous thromboembolism, particularly unprovoked venous thromboembolism, and with both severe pulmonary embolism, and subsequent chronic thromboembolic pulmonary hypertension.

IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.

IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.

Related papers